Vascular Dementia

Categories: Mental diseases, Cardiovascular diseases

Aliases & Classifications for Vascular Dementia

MalaCards integrated aliases for Vascular Dementia:

Name: Vascular Dementia 12 15
Multi-Infarct Dementia 76 54 73
Dementia, Vascular 76 44 73
Dementia, Vascular, Susceptibility to 13
Vascular Dementia, Susceptibility to 6
Dementia, Multi-Infarct 44
Multi Infarct Dementia 12
Multifocal Dementia 12
Dementia Vascular 55


Summaries for Vascular Dementia

NINDS : 54 Multi-infarct dementia (MID) is a common cause of memory loss in the elderly.  MID is caused by multiple strokes (disruption of blood flow to the brain).  Disruption of blood flow leads to damaged brain tissue.  Some of these strokes may occur without noticeable clinical symptoms. Doctors refer to these as “silent strokes.”  An individual having a silent stroke may not even know it is happening, but over time, as more areas of the brain are damaged and more small blood vessels are blocked, the symptoms of MID begin to appear.  MID can be diagnosed by an MRI or CT of the brain, along with a neurological examination. Symptoms include confusion or problems with short-term memory; wandering, or getting lost in familiar places; walking with rapid, shuffling steps; losing bladder or bowel control; laughing or crying inappropriately; having difficulty following instructions; and having problems counting money and making monetary transactions.  MID, which typically begins between the ages of 60 and 75, affects men more often than women. Because the symptoms of MID are so similar to Alzheimer’s disease, it can be difficult for a doctor to make a firm diagnosis.  Since the diseases often occur together, making a single diagnosis of one or the other is even more problematic. 

MalaCards based summary : Vascular Dementia, also known as multi-infarct dementia, is related to binswanger's disease and speech and communication disorders. An important gene associated with Vascular Dementia is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Folate Metabolism and Neuroscience. The drugs Menthol and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are homeostasis/metabolism and behavior/neurological

Disease Ontology : 12 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain.

Wikipedia : 76 Vascular dementia, also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI),... more...

Related Diseases for Vascular Dementia

Diseases related to Vascular Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Related Disease Score Top Affiliating Genes
1 binswanger's disease 31.4 ACHE APOE APP MAPT NOTCH3
2 speech and communication disorders 29.9 APOE MAPT PSEN1
4 sleep apnea 29.5 ACE APOE TNF VEGFA
5 ischemia 29.5 ACE APP PON1 VEGFA
6 frontotemporal dementia 29.3 ACHE APOE APP MAPT PSEN1
7 vascular disease 29.3 ACE APOE CST3 MTHFR PON1 TNF
8 cerebral amyloid angiopathy, cst3-related 29.1 APOE APP CST3 MAPT PSEN1
9 hydrocephalus 29.0 APOE APP MAPT MBP
10 dementia, lewy body 28.8 ACHE APOE APP BCHE MAPT PSEN1
11 heart disease 28.5 ACE APOE CST3 MTHFR PON1 TNF
12 arteries, anomalies of 28.5 ACE APOE MTHFR PON1 TNF VEGFA
13 cerebrovascular disease 28.2 ACE ACHE APOE APP MTHFR NOTCH3
14 alzheimer disease 2 27.9 APOE APP BCHE MAPT PSEN1 SERPINA3
15 alzheimer disease 27.0 ACE ACHE APOE APP BCHE CHAT
16 cerebral arteriosclerosis 11.0
17 subcortical arteriosclerotic encephalopathy 11.0
18 dementia - subcortical 10.8
19 moderate and severe traumatic brain injury 10.8 ACE APOE
20 simultanagnosia 10.8 APOE MAPT
21 posterior cortical atrophy 10.8 APOE MAPT
22 subacute cutaneous lupus erythematosus 10.7 ACE TNF
23 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 10.7
24 generalized atherosclerosis 10.7 ACE APOE
25 alzheimer disease 4 10.7 APOE PSEN1
26 skin sarcoidosis 10.7 ACE TNF
27 granulomatous dermatitis 10.6 ACE TNF
28 progressive non-fluent aphasia 10.6 MAPT PSEN1
29 behavioral variant of frontotemporal dementia 10.6 MAPT PSEN1
30 ischemic heart disease 10.6 ACE APOE TNF
31 cerebral atherosclerosis 10.6 ACE APOE MTHFR
32 cerebral palsy 10.6 APOE MTHFR TNF
33 butyrylcholinesterase deficiency 10.6 ACHE BCHE
34 hemifacial spasm 10.5 MTHFR VEGFA
35 semantic dementia 10.5 APOE MAPT PSEN1
36 aortic atherosclerosis 10.5 ACE APOE PON1
37 nominal aphasia 10.4 ACHE MAPT PSEN1
38 coronary stenosis 10.4 ACE APOE PON1
39 coronary heart disease 1 10.4 ACE APOE PON1
40 inclusion body myositis 10.4 APOE APP MAPT
41 early-onset, autosomal dominant alzheimer disease 10.4 APP PSEN1
42 cerebritis 10.4
43 pustulosis of palm and sole 10.4 CHAT TNF
44 gait apraxia 10.4 APOE APP PSEN1
45 hereditary cerebral amyloid angiopathy 10.4 APP CST3
46 critical limb ischemia 10.4 TNF VEGFA
47 atherosclerosis susceptibility 10.3 APOE PON1 TNF
48 senile plaque formation 10.3 APOE APP CHAT
49 carotid stenosis 10.3 ACE APOE MTHFR TNF
50 kluver-bucy syndrome 10.3 APP MAPT PSEN1

Comorbidity relations with Vascular Dementia via Phenotypic Disease Network (PDN):

Acute Cystitis Cerebral Atherosclerosis
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Vascular Dementia:

Diseases related to Vascular Dementia

Symptoms & Phenotypes for Vascular Dementia

MGI Mouse Phenotypes related to Vascular Dementia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.37 MBP PON1 PSEN1 MTHFR CST3 MAPT
2 behavior/neurological MP:0005386 10.33 NOTCH3 MBP MAPT ACE APP ACHE
3 growth/size/body region MP:0005378 10.3 MAPT NOTCH3 MBP MTHFR ACE APP
4 cardiovascular system MP:0005385 10.28 NOTCH3 PON1 CST3 MAPT ACE APP
5 mortality/aging MP:0010768 10.28 MBP MTHFR CST3 MAPT NOTCH3 ACE
6 hematopoietic system MP:0005397 10.21 MAPT NOTCH3 MBP ACE APP ACHE
7 integument MP:0010771 10.13 MAPT NOTCH3 MTHFR APP APOE TNF
8 nervous system MP:0003631 10.13 MBP MTHFR CST3 MAPT NOTCH3 APP
9 muscle MP:0005369 10.1 PSEN1 CST3 MAPT NOTCH3 APP ACHE
10 reproductive system MP:0005389 9.97 MBP PSEN1 MTHFR CST3 NOTCH3 APP
11 limbs/digits/tail MP:0005371 9.93 CHAT MTHFR APOE TNF PSEN1 VEGFA
12 neoplasm MP:0002006 9.85 MAPT NOTCH3 CST3 ACE TNF VEGFA
13 no phenotypic analysis MP:0003012 9.8 MAPT MTHFR APOE APP ACHE TNF
14 respiratory system MP:0005388 9.5 NOTCH3 CHAT APOE ACHE TNF PSEN1
15 vision/eye MP:0005391 9.32 MBP MTHFR MAPT NOTCH3 ACHE CHAT

Drugs & Therapeutics for Vascular Dementia

Drugs for Vascular Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Menthol Approved Phase 4,Phase 2,Phase 3 2216-51-5 16666
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
Dopamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-61-6, 62-31-7 681
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
Citalopram Approved Phase 4 59729-33-8 2771
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Corticosterone Experimental Phase 4 50-22-6 5753
12 calcium channel blockers Phase 4,Phase 2,Phase 3
13 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Muscarinic Antagonists Phase 4
15 Cholinergic Antagonists Phase 4
16 Serotonin Agents Phase 4,Phase 3
17 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Serotonin Uptake Inhibitors Phase 4
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
21 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Parasympatholytics Phase 4
23 Dopamine Agents Phase 4,Phase 2,Phase 3,Not Applicable
24 Vasodilator Agents Phase 4,Phase 2,Phase 3
25 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
26 Phosphodiesterase Inhibitors Phase 4,Phase 2
27 Antihypertensive Agents Phase 4,Phase 2,Phase 3
28 Excitatory Amino Acid Antagonists Phase 4,Not Applicable
29 Excitatory Amino Acids Phase 4,Not Applicable
30 Antidepressive Agents Phase 4
31 Antidepressive Agents, Second-Generation Phase 4
32 Antiparkinson Agents Phase 4,Phase 3,Not Applicable
33 Psychotropic Drugs Phase 4,Phase 3,Phase 2
34 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
35 Calcium, Dietary Phase 4,Phase 2,Phase 3
36 Cerebrolysin Phase 4
37 Analgesics Phase 4,Phase 2
38 Fibrinolytic Agents Phase 4
39 Respiratory System Agents Phase 4
40 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
41 Narcotic Antagonists Phase 4
42 Narcotics Phase 4
43 Neuroprotective Agents Phase 4,Phase 3
44 Cyclooxygenase Inhibitors Phase 4
45 Analgesics, Non-Narcotic Phase 4,Phase 2
46 Analgesics, Opioid Phase 4
47 Anti-Asthmatic Agents Phase 4
48 Pharmaceutical Solutions Phase 4
49 Phosphodiesterase 3 Inhibitors Phase 4
50 Platelet Aggregation Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
2 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
3 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
4 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
5 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4 Cilostazol;Aspirin
6 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
7 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
8 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
9 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
10 Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Unknown status NCT02453932 Phase 3 Tianzhi granule and placebo identified to donepezil;Donepezil and placebo identified to Tianzhi granule;Placebo
11 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
12 Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3 Rivastigmine
13 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3 Rivastigmine
14 A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia Completed NCT00261573 Phase 3 galantamine hydrobromide
15 A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3 galantamine
16 Seroquel- Agitation Associated With Dementia Completed NCT00621647 Phase 3 Quetiapine Fumarate;Quetiapine Fumarate;Placebo
17 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249158 Phase 3 Risperidone
18 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3 Metformin
19 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
20 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249145 Phase 3 risperidone
21 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00253123 Phase 3 risperidone
22 Risk Reduction for Alzheimer's Disease Recruiting NCT02913664 Phase 2, Phase 3 Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine);Atorvastatin
23 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
24 Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function Recruiting NCT03082014 Phase 3 Amlodipine;Losartan;Atenolol
25 MIND Diet Intervention and Cognitive Decline Active, not recruiting NCT02817074 Phase 3
26 Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Unknown status NCT01761227 Phase 2 Fufangdanshen Tablets;Placebo
27 The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule Unknown status NCT01978730 Phase 2 high dose group of SaiLuoTong capsule;low dose group of SaiLuoTong;the control group
28 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
29 Safety Study of Dabigatran in CADASIL Unknown status NCT01361763 Phase 2 Dabigatran;Antiplatelets
30 Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) Completed NCT01475578 Phase 2 STA-1;Ergoloid Mesylates tablet
31 Effect of Insulin Sensitizer Metformin on AD Biomarkers Completed NCT01965756 Phase 2 Metformin;Placebos
32 DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia Completed NCT02103673 Phase 2 DAOIB;Placebo
33 Oxidative Stress and Nutritional Supplementation Intervention Study Completed NCT01234506 Phase 2
34 Delta-THC in Dementia Completed NCT01608217 Phase 2 delta-9-tetrahydrocannabinol (delta-THC);Placebo;Acetaminophen;Acetaminophen
35 The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment Completed NCT00103948 Phase 2 Aricept
36 A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Recruiting NCT02886494 Phase 2 BAC;Matched placebo
37 n-3 PUFA for Vascular Cognitive Aging Active, not recruiting NCT01953705 Phase 2 Omega 3 PUFA;Placebo
38 Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia Not yet recruiting NCT03230071 Phase 2 TMBCZG
39 BAC in Patient With Alzheimer's Disease or Vascular Dementia Not yet recruiting NCT02467413 Phase 2 BAC
40 Aricept to Improve Functional Tasks in Vascular Dementia Unknown status NCT00457769 Phase 1 Donepezil;Donepezil
41 Blood-brain Barrier Leakage in Dementia. A Dynamic Contrast-enhanced MRI Study Unknown status NCT02018913
42 Hyperbaric Oxygen Therapy for Mild Cognitive Impairment Unknown status NCT02085330 Not Applicable
43 Cognition And Neocortical Volume After Stroke Unknown status NCT02205424
44 MRS and DTI of White Matter in Alzheimer's Disease Unknown status NCT00172900
45 Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 (Follow-up Studie) Unknown status NCT01126775
46 Efficiency Study of Siwu Tang to Treat Brain Hypoperfusion Syndrome Unknown status NCT01221662 Not Applicable Siwu Tang
47 Cognitive Training in Aging Unknown status NCT02205710 Not Applicable
48 Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI) Unknown status NCT02819700
49 Memantine on Aggression and Agitation of Alzheimer's Disease (AD) Unknown status NCT00703430 Not Applicable Memantine
50 Atrial Fibrillation and the Risk for Neurological Complications Unknown status NCT00357227

Search NIH Clinical Center for Vascular Dementia

Cochrane evidence based reviews: dementia, vascular

Genetic Tests for Vascular Dementia

Anatomical Context for Vascular Dementia

MalaCards organs/tissues related to Vascular Dementia:

Brain, Testes, Cortex, Heart, Eye, Prostate, Skin

Publications for Vascular Dementia

Articles related to Vascular Dementia:

(show top 50) (show all 836)
# Title Authors Year
Vascular dementia: clinicopathologic and genetic considerations. ( 29380913 )
Predicting outcome of Morris water maze test in vascular dementia mouse model with deep learning. ( 29415035 )
Chinese Herbal Medicine for Vascular Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. ( 29439346 )
Genomea89wide DNA methylation profiling in a rat model with vascular dementia. ( 29749552 )
Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats. ( 29778746 )
Stroke Risk and Vascular Dementia in South Asians. ( 29974259 )
Potential of carnosine, a histamine precursor in rat model of bilateral common carotid artery occlusion-induced vascular dementia. ( 29676814 )
Sleep Apnea Is a Risk Factor for Stroke and Vascular Dementia. ( 29938308 )
The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia. ( 29759140 )
Distinct Patterns of Rich Club Organization in Alzheimer's Disease and Subcortical Vascular Dementia: A White Matter Network Study. ( 29710719 )
FoxO1-mediated autophagy plays an important role in the neuroprotective effects of hydrogen in a rat model of vascular dementia. ( 29885845 )
Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. ( 29372037 )
Lower Plasma Klotho Concentrations Are Associated with Vascular Dementia but Not Late-Onset Alzheimer's Disease. ( 29768278 )
Factors associated with type 2 diabetes in patients with vascular dementia: a population-based cross-sectional study. ( 29973163 )
<i>Panax ginseng</i> extract attenuates neuronal injury and cognitive deficits in rats with vascular dementia induced by chronic cerebral hypoperfusion. ( 29722318 )
Herbal medicine as a promising therapeutic approach for the management of vascular dementia: A systematic literature review. ( 29786916 )
Tau pathology and neurochemical changes associated with memory dysfunction in an optimised murine model of global cerebral ischaemia - A potential model for vascular dementia? ( 29649504 )
Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer's and Vascular Dementia Drugs. ( 29401682 )
Albuminuria Increases the Risks for Both Alzheimer Disease and Vascular Dementia in Community-Dwelling Japanese Elderly: The Hisayama Study. ( 29353232 )
Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. ( 29933741 )
Repeated administration of Sailuotong, a fixed combination of Panax ginseng, Ginkgo biloba, and Crocus sativus extracts for vascular dementia, alters CYP450 activities in rats. ( 29425645 )
Acupuncture Prevents the Impairment of Hippocampal LTP Through I^1-AR in Vascular Dementia Rats. ( 29435917 )
Diagnostic relevance of spatial orientation for vascular dementia: A case study. ( 29682239 )
Neuropsychiatric symptoms in vascular dementia: Epidemiologic and clinical aspects. ( 29682232 )
Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia. ( 29247598 )
Specific Patterns of White Matter Alterations Help Distinguishing Alzheimer's and Vascular Dementia. ( 29922120 )
Intermittent streptozotocin administration induces behavioral and pathological features relevant to Alzheimer's disease and vascular dementia. ( 29738850 )
Efficacy and safety of the compound Chinese medicine SaiLuoTong inA vascular dementia: A randomized clinical trial. ( 29955654 )
Puerarin up-regulates methyl-CpG binding protein 2 phosphorylation in hippocampus of vascular dementia rats. ( 29327124 )
Nanotherapy for Alzheimer's disease and vascular dementia: Targeting senile endothelium. ( 29274774 )
Mitochondrial factor and cell cytokines associate with TCM syndrome scale in vascular dementia patients. ( 29375680 )
The potential protective effects of cannabinoid receptor agonist WIN55,212-2 on cognitive dysfunction is associated with the suppression of autophagy and inflammation in an experimental model of vascular dementia. ( 29945070 )
Effect of Telmisartan on Preventing Learning and Memory Deficits Via Peroxisome Proliferator-Activated Receptor-I^ in Vascular Dementia Spontaneously Hypertensive Rats. ( 29241675 )
Cognitive impairment in Parkinson's disease, Alzheimer's dementia, and vascular dementia: the role of the clock-drawing test. ( 29417704 )
Efficacy of cognitive stimulation therapy for older adults with vascular dementia. ( 29354225 )
Prevention of hypertension-induced vascular dementia by Lactobacillus paracasei subsp. paracasei NTU 101-fermented products. ( 27937042 )
Astrocyte-derived lipocalin-2 mediates hippocampal damage and cognitive deficits in experimental models of vascular dementia. ( 28581123 )
Effect of hippocampal La89NBP on BDNF and TrkB expression and neurological function of vascular dementia rats. ( 28944854 )
Circulating microRNAs as potential biomarkers for the identification of vascular dementia due to cerebral small vessel disease. ( 28633305 )
Vitamin B6 prevents isocarbophos-induced vascular dementia in rats through N-methyl-D-aspartate receptor signaling. ( 28872356 )
Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia. ( 28634464 )
Color vision test to differentiate Alzheimer's disease from vascular dementia. ( 28625199 )
Serum homocysteine levels in patients with probable vascular dementia. ( 28786967 )
Resveratrol loaded solid lipid nanoparticles attenuate mitochondrial oxidative stress in vascular dementia by activating Nrf2/HO-1 pathway. ( 28782592 )
Neuropsychological Profiles Differentiate Alzheimer Disease from Subcortical Ischemic Vascular Dementia in an Autopsy-Defined Cohort. ( 28595184 )
Vascular parkinsonism and vascular dementia are associated with an increased risk of vascular events or death. ( 28905043 )
White matter damage and glymphatic dysfunction in a model of vascular dementia in rats with no prior vascular pathologies. ( 27940353 )
Correlations between Gray Matter and White Matter Degeneration in Pure Alzheimer's Disease, Pure Subcortical Vascular Dementia, and Mixed Dementia. ( 28842654 )
Synergistic effect of tanshinone IIA and mesenchymal stem cells on preventing learning and memory deficits via anti-apoptosis, attenuating tau phosphorylation and enhancing the activity of central cholinergic system in vascular dementia. ( 27845241 )
Evolution of short cognitive test performance in stroke patients with vascular cognitive impairment and vascular dementia: Baseline evaluation and follow-up. ( 29354218 )

Variations for Vascular Dementia

ClinVar genetic disease variations for Vascular Dementia:

# Gene Variation Type Significance SNP ID Assembly Location
1 TNF NM_000594.3(TNF): c.-1037C> T single nucleotide variant risk factor rs1799724 GRCh37 Chromosome 6, 31542482: 31542482
2 TNF NM_000594.3(TNF): c.-1037C> T single nucleotide variant risk factor rs1799724 GRCh38 Chromosome 6, 31574705: 31574705

Expression for Vascular Dementia

Search GEO for disease gene expression data for Vascular Dementia.

Pathways for Vascular Dementia

GO Terms for Vascular Dementia

Cellular components related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.89 ACHE APP PSEN1 TNF VEGFA
2 axon GO:0030424 9.81 APP CST3 MAPT PSEN1
3 endoplasmic reticulum lumen GO:0005788 9.78 APOE APP BCHE CST3
4 growth cone GO:0030426 9.7 APP MAPT PSEN1
5 extracellular space GO:0005615 9.65 ACE ACHE APOE APP BCHE CST3
6 blood microparticle GO:0072562 9.62 APOE BCHE PON1 SERPINA3
7 platelet alpha granule lumen GO:0031093 9.58 APP SERPINA3 VEGFA
8 neuronal cell body GO:0043025 9.55 APOE CST3 MAPT MBP PSEN1
9 neuromuscular junction GO:0031594 9.54 ACHE APP PSEN1
10 ciliary rootlet GO:0035253 9.46 APP PSEN1
11 nuclear envelope lumen GO:0005641 9.43 APP BCHE
12 extracellular region GO:0005576 9.4 ACE ACHE APOE APP BCHE CST3
13 main axon GO:0044304 9.26 APP MAPT

Biological processes related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.87 APOE APP CST3 PSEN1
2 negative regulation of endopeptidase activity GO:0010951 9.84 APP CST3 SERPINA3
3 negative regulation of peptidase activity GO:0010466 9.83 APP CST3 SERPINA3
4 platelet degranulation GO:0002576 9.83 APP SERPINA3 VEGFA
5 Notch signaling pathway GO:0007219 9.83 APP NOTCH3 PSEN1
6 response to toxic substance GO:0009636 9.82 CST3 MBP PON1
7 positive regulation of protein phosphorylation GO:0001934 9.81 APP PSEN1 TNF VEGFA
8 cholesterol metabolic process GO:0008203 9.79 APOE APP PON1
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 APP TNF VEGFA
10 forebrain development GO:0030900 9.76 APP NOTCH3 PSEN1
11 positive regulation of MAP kinase activity GO:0043406 9.72 PSEN1 TNF VEGFA
12 response to oxidative stress GO:0006979 9.71 APOE APP CST3 PSEN1
13 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 APOE TNF
14 synapse organization GO:0050808 9.65 APP MAPT PSEN1
15 negative regulation of gene expression GO:0010629 9.65 APOE APP MAPT TNF VEGFA
16 positive regulation of cholesterol efflux GO:0010875 9.64 APOE PON1
17 amyloid-beta metabolic process GO:0050435 9.63 ACE PSEN1
18 neurotransmitter biosynthetic process GO:0042136 9.63 ACHE CHAT
19 supramolecular fiber organization GO:0097435 9.62 CST3 MAPT
20 Notch receptor processing, ligand-dependent GO:0035333 9.62 NOTCH3 PSEN1
21 amyloid fibril formation GO:1990000 9.6 APP MAPT
22 response to folic acid GO:0051593 9.59 BCHE MTHFR
23 negative regulation of long-term synaptic potentiation GO:1900272 9.58 APOE APP
24 modulation of age-related behavioral decline GO:0090647 9.56 APP PSEN1
25 neuron projection maintenance GO:1990535 9.54 APP PSEN1
26 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.52 ACE VEGFA
27 artery morphogenesis GO:0048844 9.5 APOE NOTCH3 VEGFA
28 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.49 APP PSEN1
29 astrocyte activation involved in immune response GO:0002265 9.46 APP PSEN1
30 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.43 APP PSEN1
31 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.37 APP PSEN1
32 amyloid precursor protein metabolic process GO:0042982 9.33 ACHE APOE PSEN1
33 astrocyte activation GO:0048143 9.13 APP MAPT PSEN1
34 positive regulation of amyloid fibril formation GO:1905908 8.8 APOE APP PSEN1

Molecular functions related to Vascular Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.73 APP BCHE MAPT NOTCH3
2 peptidase inhibitor activity GO:0030414 9.58 APP CST3 SERPINA3
3 identical protein binding GO:0042802 9.56 APOE APP BCHE CST3 MAPT NOTCH3
4 protease binding GO:0002020 9.54 CST3 MBP TNF
5 lipoprotein particle binding GO:0071813 9.32 APOE MAPT
6 cholinesterase activity GO:0004104 9.26 ACHE BCHE
7 acetylcholinesterase activity GO:0003990 9.16 ACHE BCHE
8 amyloid-beta binding GO:0001540 8.92 ACHE APOE BCHE CST3

Sources for Vascular Dementia

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....